Answer by the authors to the letter of Dr. Wang and colleagues, concerning our case report entitled “Idarucizumab for dabigatran overdose”

"Answer by the authors to the letter of Dr. Wang and colleagues, concerning our case report entitled “Idarucizumab for dabigatran overdose”." Clinical Toxicology, 55(1), p. 66

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.